2016年法国制药公司向全科医生赠送礼品与其处方模式之间的关联:基于法国医疗透明与国民健康数据系统的回顾性研究
该回顾性研究利用法国两个数据库,评估2016年制药公司向41257名私人执业全科医生赠送礼品与其处方模式之间的关联。结果显示,未收礼组较收礼组每诊次报销药费更低、仿制药抗生素及他汀等处方效率指标更优,但研究存在残余混杂,不能得出因果结论。
要点
- 未收礼组每诊次报销药费较≥1000欧元组低5.33欧元(99.9%CI -6.99至-3.66)。
- 未收礼组仿制药抗生素处方率较≥1000欧元组高2.17%(99.9%CI 1.47%至2.88%)。
- 未收礼组他汀处方率较≥1000欧元组高12.14%(99.9%CI 11.03%至13.26%)。
核心结论
- 研究提示,未接受制药公司礼品的法国全科医生具有更好的处方效率指标且处方费用更低。
- 该观察性研究易受残余混杂影响,不能得出因果结论。
研究设计与样本
- 回顾性研究,使用法国国民健康数据系统与医疗透明数据库。
- 纳入2016年完全在私人部门执业且至少有5名注册患者的41257名全科医生。
- 按医疗透明数据库中制药、医疗器械及其他健康相关公司报告的礼品金额将全科医生分为六组。
主要发现
- 未收礼组每诊次报销药费较2016年≥1000欧元组低5.33欧元(99.9%CI -6.99至-3.66,P<0.001)。
- 未收礼组仿制药抗生素处方率较≥1000欧元组高2.17%(99.9%CI 1.47%至2.88%,P<0.001)。
- 未收礼组降压药处方率较≥1000欧元组高4.24%(99.9%CI 3.72%至4.77%,P<0.001)。
- 未收礼组他汀处方率较≥1000欧元组高12.14%(99.9%CI 11.03%至13.26%,P<0.001)。
- 未收礼组较2016年≥240欧元组更少处方超过12周的地西泮类(-0.68%,99.9%CI -1.13%至-0.23%)和血管扩张剂(-0.15%,99.9%CI -0.28%至-0.03%),且ACE抑制剂占所有ACE抑制剂与沙坦类处方的比例较≥1000欧元组高1.67%(99.9%CI 0.62%至2.71%,P<0.001)。
关键数值与推荐
- 主要结局为每诊次(诊所或上门)法国国民健康保险报销的药费金额及11项处方效率指标。
- 统计分析显著性阈值设为0.001。
- 阿司匹林、仿制药抗抑郁药及仿制药质子泵抑制剂处方的组间差异不显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 该观察性研究易受残余混杂影响,因此不能得出因果结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association between gifts from pharmaceutical companies to French general practitioners (GPs) and their drug prescribing patterns. DESIGN: Retrospective study using data from two French databases (National Health Data System, managed by the French National Health Insurance system, and Transparency in Healthcare). SETTING: Primary care, France. PARTICIPANTS: 41 257 GPs who in 2016 worked exclusively in the private sector and had at least five registered patients. The GPs were divided into six groups according to the monetary value of the received gifts reported by pharmaceutical, medical device, and other health related companies in the Transparency in Healthcare database. MAIN OUTCOME MEASURES: The main outcome measures were the amount reimbursed by the French National Health Insurance for drug prescriptions per visit (to the practice or at home) and 11 drug prescription efficiency indicators used by the National Health Insurance to calculate the performance related financial incentives of the doctors. Doctor and patient characteristics were used as adjustment variables. The significance threshold was 0.001 for statistical analyses. RESULTS: The amount reimbursed by the National Health Insurance for drug prescriptions per visit was lower in the GP group with no gifts reported in the Transparency in Healthcare database in 2016 and since its launch in 2013 (no gift group) compared with the GP groups with at least one gift in 2016 (-€5.33 (99.9% confidence interval -€6.99 to -€3.66) compared with the GP group with gifts valued at €1000 or more reported in 2016) (P<0.001). The no gift group also more frequently prescribed generic antibiotics (2.17%, 1.47% to 2.88% compared with the ≥€1000 group), antihypertensives (4.24%, 3.72% to 4.77% compared with the ≥€1000 group), and statins (12.14%, 11.03% to 13.26% compared with the ≥€1000 group) than GPs with at least one gift between 2013 and 2016 (P<0.001). The no gift group also prescribed fewer benzodiazepines for more than 12 weeks (-0.68%, -1.13% to -0.23% compared with the €240-€999 group) and vasodilators (-0.15%, -0.28% to -0.03% compared with the ≥€1000 group) than GPs with gifts valued at €240 or more reported in 2016, and more angiotensin converting enzyme (ACE) inhibitors compared with all ACE and sartan prescriptions (1.67%, 0.62% to 2.71%) compared with GPs with gifts valued at €1000 or more reported in 2016 (P<0.001). Differences were not significant for the prescription of aspirin and generic antidepressants and generic proton pump inhibitors. CONCLUSION: The findings suggest that French GPs who do not receive gifts from pharmaceutical companies have better drug prescription efficiency indicators and less costly drug prescriptions than GPs who receive gifts. This observational study is susceptible to residual confounding and therefore no causal relation can be concluded. TRIAL REGISTRATION: OSF register OSF.IO/8M3QR.
引用
- Goupil B, Balusson F, Naudet F, et al. Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases. BMJ. 2019. PMID: 31690553. doi:10.1136/bmj.l6015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。